Transgene presented additional Phase I Data with TG4050 at ASCO 2022
Category: 2022
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
JP Delord, et al. ASCO 2022 Abstract available on the ASCO website – Download the poster here Poster Presentation
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
Transgene presented additional Phase I Data with TG4050 at ASCO 2022
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Transgene to present updated positive preliminary data at ASCO 2022
Transgene’s Combined General Meeting of May 25, 2022
Transgene’s combined general meeting of May 25, 2022
Transgene Announces Upcoming Investor Meetings
Transgene annonces upcoming investor meetings
All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022
All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination
Rodrigo Nalio Ramos, et al. Clinical and Translational Immunology, May 8 2022 – Read the article Publication
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
MS Block et al. AACR 2022 Download the publication here
Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
JB Marchand et al.AACR 2022Read the abstract here – Download the poster herePoster Presentation
